- Home
- RARE vs KGS Comparison
RARE vs KGS Comparison
Compare RARE & KGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- KGS
- Stock Information
- Founded
- RARE 2010
- KGS 2011
- Country
- RARE United States
- KGS United States
- Employees
- RARE N/A
- KGS N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- KGS
- Sector
- RARE Health Care
- KGS
- Exchange
- RARE Nasdaq
- KGS Nasdaq
- Market Cap
- RARE 4.2B
- KGS 3.8B
- IPO Year
- RARE 2014
- KGS 2023
- Fundamental
- Price
- RARE $42.59
- KGS $43.69
- Analyst Decision
- RARE Strong Buy
- KGS Strong Buy
- Analyst Count
- RARE 15
- KGS 11
- Target Price
- RARE $93.13
- KGS $41.09
- AVG Volume (30 Days)
- RARE 656.5K
- KGS 1.2M
- Earning Date
- RARE 02-13-2025
- KGS 03-05-2025
- Dividend Yield
- RARE N/A
- KGS 3.75%
- EPS Growth
- RARE N/A
- KGS N/A
- EPS
- RARE N/A
- KGS 0.26
- Revenue
- RARE $560,230,000.00
- KGS $1,075,772,000.00
- Revenue This Year
- RARE $19.26
- KGS $39.35
- Revenue Next Year
- RARE $36.92
- KGS $16.03
- P/E Ratio
- RARE N/A
- KGS $168.26
- Revenue Growth
- RARE 29.01
- KGS 33.77
- 52 Week Low
- RARE $37.02
- KGS $23.57
- 52 Week High
- RARE $60.37
- KGS $50.43
- Technical
- Relative Strength Index (RSI)
- RARE 44.76
- KGS 43.76
- Support Level
- RARE $41.73
- KGS $44.02
- Resistance Level
- RARE $44.98
- KGS $47.05
- Average True Range (ATR)
- RARE 1.72
- KGS 1.51
- MACD
- RARE -0.04
- KGS -0.43
- Stochastic Oscillator
- RARE 18.03
- KGS 4.60
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About KGS Kodiak Gas Services Inc.
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Compression Operations and Other Services. Compression Operations consist of operating company-owned and customer-owned compression infrastructure for customers, pursuant to fixed-revenue contracts to enable the production, gathering and transportation of natural gas and oil. Other Services consist of a full range of contract services to support the needs of customers, including station construction, maintenance and overhaul and other ancillary time and material-based offerings.